Systemic Treatment With Everolimus for the Prevention of MACE After Bare Metal Stent Implantation

Inclusion Criteria:

1. Males or females, aged >18 years.

2. Patients with coronary artery disease who are scheduled for coronary intervention withbare metal stent placement for treatment of de novo or first restenosis in a nativecoronary artery.

3. Target lesion must be in a native coronary vessel of 2.25 – 4.0 mm size.

4. Target lesion has to be of less than or equal to 25 mm length.

5. Tandem lesion may be included as long as:

• overall length is less than or equal to 25 mm

• tandem lesion will be treated with one stent and counted as one lesion.

Exclusion Criteria: The following exclusion criteria must not be present at Baseline visit 1 (BL1, Screeningvisit prior to coronary intervention). If an exclusion criterion occurred afterwards, e.g.,during the coronary intervention, the patient must be excluded from the study.

1. Target lesion has a reference vessel size of less than 2.25 or more than 4.0 mmdiameter.

2. Target lesion is a total occlusion or located at a bifurcation.

3. Treatment affords implantation of more than one stent per treated lesion.

4. Target lesion was already treated by brachytherapy.

5. Target lesion has one or more of the following criteria:

• Left main lesion

• Ostial lesion of the RCA

• Located at less than 2 mm after the origin of the LAD or RCX. Other protocol defined inclusion/exclusion criteria may apply.